RISK OF 2ND AERODIGESTIVE CANCERS INCREASES IN PATIENTS WHO SURVIVE FREE OF SMALL-CELL LUNG-CANCER FOR MORE THAN 2 YEARS

被引:49
作者
JOHNSON, BE
LINNOILA, RI
WILLIAMS, JP
VENZON, DJ
OKUNIEFF, P
ANDERSON, GB
RICHARDSON, GE
机构
[1] NCI, BIOMARKERS & PREVENT RES BRANCH, BETHESDA, MD 20892 USA
[2] NCI, RADIAT ONCOL BRANCH, BETHESDA, MD 20892 USA
[3] NCI, BIOSTAT & DATA MANAGEMENT SECT, BETHESDA, MD 20892 USA
[4] NATL NAVAL MED CTR, DEPT PATHOL, BETHESDA, MD USA
[5] NATL NAVAL MED CTR, DEPT MED, BETHESDA, MD USA
关键词
D O I
10.1200/JCO.1995.13.1.101
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: patients who survived small-cell lung cancer (SCLC) for more than 2 years were evaluated to determine the frequency and anatomic pattern of redevelopment of smell-cell cancer and development of nonsmall-cell lung cancer (NSCLC) and aerodigestive cancers with the passage of time. Patients and Methods: From April 1973 through December 1991, 578 patients with previously untreated SCLC were entered onto prospective therapeutic trials at the National Cancer Institute (NCI), Bethesda, MD, Sixty-two (11%) were cancer-free 2 years after initiation of therapy and were assessable for redevelopment of SCLC and development of NSCLC, and aerodigestive cancers. Results: Twenty patients redeveloped SCLC 2.0 to 12.2 years after initiation of chemotherapy, of whom two patients were deemed to have a second primary small-cell cancer that involved the aerodigestive tract. Fifteen patients developed 16 cancers in the lung other than SCLC 3.4 to 14.9 years after initiation of therapy. Two developed other aerodigestive cancers that involved the larynx and lip. The risk of a NSCLC and aerodigestive cancer in these patients increased more than sixfold from 2% per patient per year during years 2 to 4 to 12.6% and 14.4%, respectively, after more than 10 years. The cumulative actuarial risk of a second primary NSCLC or aerodigestive cancer at 16 years is 69% and 72%, respectively. Conclusion: The increasing risk of second aerodigestive cancers with the passage of time is a mounting problem for patients cured of SCLC. Chemoprevention trials for these patients should be considered.
引用
收藏
页码:101 / 111
页数:11
相关论文
共 46 条
[1]   2ND MALIGNANCIES AFTER TREATMENT OF HODGKINS-DISEASE - THE INFLUENCE OF TREATMENT, FOLLOW-UP TIME, AND AGE [J].
ABRAHAMSEN, JF ;
ANDERSEN, A ;
HANNISDAL, E ;
NOME, O ;
ABRAHAMSEN, AF ;
KVALOY, S ;
HOST, H .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (02) :255-261
[2]   LONG-TERM SURVIVAL AND TOXICITY IN SMALL-CELL LUNG-CANCER - EXPANDED SOUTHWEST-ONCOLOGY-GROUP EXPERIENCE [J].
ALBAIN, KS ;
CROWLEY, JJ ;
LIVINGSTON, RB .
CHEST, 1991, 99 (06) :1425-1432
[3]   TREATMENT OF EXTENSIVE STAGE SMALL CELL BRONCHOGENIC-CARCINOMA - EFFECTS OF VARIATION IN INTENSITY OF INDUCTION CHEMOTHERAPY [J].
BROWER, M ;
IHDE, DC ;
JOHNSTONEARLY, A ;
BUNN, PA ;
COHEN, MH ;
CARNEY, DN ;
MAKUCH, RW ;
MATTHEWS, MJ ;
RADICE, PA ;
MINNA, JD .
AMERICAN JOURNAL OF MEDICINE, 1983, 75 (06) :993-1000
[4]   CHEMOTHERAPY ALONE OR CHEMOTHERAPY WITH CHEST RADIATION-THERAPY IN LIMITED STAGE SMALL-CELL LUNG-CANCER - A PROSPECTIVE, RANDOMIZED TRIAL [J].
BUNN, PA ;
LICHTER, AS ;
MAKUCH, RW ;
COHEN, MH ;
VEACH, SR ;
MATTHEWS, MJ ;
ANDERSON, AJ ;
EDISON, M ;
GLATSTEIN, E ;
MINNA, JD ;
IHDE, DC .
ANNALS OF INTERNAL MEDICINE, 1987, 106 (05) :655-662
[5]  
CATANE R, 1981, CANCER-AM CANCER SOC, V48, P1936, DOI 10.1002/1097-0142(19811101)48:9<1936::AID-CNCR2820480904>3.0.CO
[6]  
2-W
[7]  
COHEN MH, 1977, CANCER TREAT REP, V61, P349
[8]  
COHEN MH, 1979, CANCER TREAT REP, V63, P163
[9]  
Cox D.R., 1974, THEORETICAL STAT
[10]   2ND PRIMARY BRONCHOGENIC CARCINOMAS AFTER SMALL CELL-CARCINOMA - REPORT OF 2 CASES AND REVIEW OF THE LITERATURE [J].
CRAIG, J ;
POWELL, B ;
MUSS, HB ;
KAWAMOTO, E ;
BREYER, R .
AMERICAN JOURNAL OF MEDICINE, 1984, 76 (06) :1013-1020